Global Anterior Uveitis Treatment Market Outlook 2031:
The Global Anterior Uveitis Treatment Market size was valued at USD 700 Million in 2022 and is projected to reach USD 1.25 Billion by 2031, expanding at a CAGR of 6.7% during the forecast period 2023 - 2031. The growth of the market is attributed to Increasing prevalence of anterior uveitis across the globe.
Uveitis is a group of inflammatory diseases that destroys eye tissues and causes uvea (middle layer of eye) swelling. These diseases can sometimes lead to severe vision loss. The various types of uveitis are posterior uveitis, anterior uveitis, panuveitis uveitis, and intermediate uveitis. Some diseases such as AIDS, multiple sclerosis, rheumatoid arthritis, tuberculosis, and ulcerative colitis increases the risk of uveitis.
Anterior uveitis affects the front, colored part of the eye, the iris and hence, it is also known as iritis. It is commonly seen in young and middle-aged people. The common symptoms of anterior uveitis include pain, photophobia, redness, decreased vision, and lacrimation. These symptoms if not treated can result in permanent blindness.
Anterior Uveitis Treatment Market Trends, Drivers, Restraints, and Opportunities:
- Favorable government regulations and growing geriatric population is estimated to contribute to the market growth during the forecast period.
- Ongoing developments in the applications of products and treatment modalities are expected to provide long term opportunity for the market growth.
- Factors such as lack of knowledge about eye-related diseases, steep prices of medications, unavailability of health insurance in some developing countries, and side effects of medication including watery eyes and irritation are expected to hinder the market growth.
Scope of the Anterior Uveitis Treatment Market report:
The report on anterior uveitis treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities and revenue forecast
|
Anterior Uveitis Treatment Market Segment Insights:
Several advantages of corticosteroids over other treatments are driving the segmental growth
Based on treatment types, the global anterior uveitis treatment market can be bifurcated into corticosteroids, cycloplegic agents, anti-tnf agents, and immunosuppressants. The corticosteroids segment held a significant market share, as they are first line therapies for anterior uveitis. Corticosteroids are inexpensive, potent, and act fast.
Moreover, they may be administered systematically (oral, intramuscular or intravenous routes), topically, or through periocular injections. Furthermore, corticosteroids are mostly preferred over biologics. Hence, the segment is expected to expand at a substantial CAGR during the forecast period.
Online pharmacies segment is expected to register higher CAGR during the forecast period
On the basis of distribution channels, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies segment is expected to expand at a significant CAGR during the forecast period.
The growth of the segment is attributed to the increasing popularity of online pharmacies owing to the advantages such as convenience, time saving, low price, and insights on the usage of drugs. Moreover, increasing number of Internet users and higher dependency on online goods are expected to boost the market growth during the forecast period.
North America is expected to account for a significant share of the global market
Based on regions, the global anterior uveitis treatment market is fragmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the highest market share and is projected to expand at a moderate CAGR during the forecast period.
Growing prevalence of the diseases in the US and presence of key market players in this region is expected to contribute to the regional growth during the forecast period. Moreover, the approval of drugs and development of new methods such as step cell therapy for the treatment of anterior uveitis is driving the market growth across the region.
Segments
The global anterior uveitis treatment market has been divided based on treatment types, distribution channels, and regions.
By Treatment Types
- Corticosteroids
- Cycloplegic Agents
- Anti-TNF Agents
- Immunosuppressants
By Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
By Key Players
- Santen Pharmaceutical Co. Ltd.
- AbbVie Inc.
- Novartis AG
- Eyegate Pharmaceuticals Inc.
- Aldeyra Therapeutics Inc.
- Aciont Inc.
- Clearside Biomedical Inc.
- Sirion Therapeutics Inc.
- Lux Biosciences Inc.
- Bausch & Lomb Incorporated
- UCB Biopharma S.P.R.L.
- EyePoint Pharmaceuticals Inc.
- Alimera Sciences Inc.
- Regeneron Pharmaceuticals
Competitive Landscape
Key players in the global anterior uveitis treatment market includes Santen Pharmaceutical Co., Ltd., AbbVie Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Aldeyra Therapeutics, Inc., Aciont Inc., Clearside Biomedical, Inc., Sirion Therapeutics, Inc., Lux Biosciences, Inc., Bausch & Lomb Incorporated, UCB Biopharma S.P.R.L., EyePoint Pharmaceuticals, Inc., Alimera Sciences Inc., and Regeneron Pharmaceuticals.
Collaborations, mergers, acquisitions, agreements, and partnerships are strategies adopted by these players to strengthen their geographical presence.